Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2010

View Archived Issues

Several phase II/III trials show safety and efficacy of fingolimod in relapsing-remitting MS

Ganglioside vaccine NeuGcGM3/VSSP shows promise in melanoma

MEDI-8662 and CAIV-T flu vaccines demonstrate comparable safety/immunogenicity in phase III trial

FDA accepts for review GSK's response regarding Horizant in restless legs syndrome

Array Biopharma discloses promising preclinical data on ARRY-575

Pentraxin-3 has therapeutic activity in mice with P. aeruginosa lung infection

PCI-45292 more potent than PCI-32765 in arthritis models

Biocartis and bioMerieux partner to develop molecular diagnostics

Prana Biotechnology plans to conduct phase IIb PBT-2 trial in Alzheimer's disease

EVP-6124 enhances cognition as coagonist with acetylcholine

Boehringer Ingelheim claims new chemokine CCR3 receptor antagonists

FDA supports Pozen's design of phase III PA-32540 trial

Merck Serono discovers new DHOdehase inhibitors

New allosteric modulators of metabotropic glutamate mGlu1 receptor claimed

Ardea Biosciences reports data on RDEA-594 in gout

Pfizer presents novel mineralocorticoid receptor antagonists

Aeterna Zentaris identifies new quinaxoline derivatives for cancer therapy

Lilly to acquire Avid Radiopharmaceuticals

Raptor Pharma begins phase II DR cysteamine trial in Huntington's disease

StemCells to receive U.S. government grants to support stem cell projects

Genta begins phase IIb tesetaxel trial in metastatic breast cancer

Clinuvel receives FDA guidance on Scenesse program in erythropoietic protoporphyria

FDA approves IND for phase I/II development of RetinoStat in wet AMD

Results reported from phase III BLOOM-DM weight loss study in type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...